Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Feeling The August Reform Heat: PhRMA And Insurers Get Scorching Letters From Congress

Executive Summary

Those involved in pushing comprehensive health care reform have taken a lot of heat this summer, and insurers and drug manufacturers are no exception

You may also be interested in...

Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill

The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole

Rx Contribution To Health Reform May Be $100 Bil. After All, Obama Suggests

What's another $20 billion among friends? Biopharma executives had to cringe when, during his July 22 press conference on health reform, President Obama discussed the industry's pledge to deliver $80 billion in savings to help fund the effort. Not only was there a rough edge to his description of the agreement, the President seemingly upped the amount industry may end up having to put on the table by 25 percent

House Takes Up PhRMA Offer For Rx Discounts In Donut Hole, But Still Wants More Rebates

House health reform bill includes PhRMA's offer of 50 percent discounts on drugs for Medicare beneficiaries in the Part D donut hole, but also contains Medicaid-level rebates on drugs used by dual-eligibles.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts